TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Chimeric Therapeutics Ltd. ( (AU:CHM) ).
Chimeric Therapeutics announced significant board changes following shareholder feedback from its recent AGM, including the appointment of a new Chairperson and a Non-Executive Director nominated by a major shareholder. The company is optimistic about its future as it progresses its CHM CDH17 Phase 1/2 trial, which is showing promising results in tumor shrinkage and disease control, with more data expected soon.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. is an Australian leader in cell therapy, focusing on the development and commercialization of innovative cancer treatments. The company has a diversified portfolio that includes first-in-class autologous CAR T cell therapies and best-in-class allogeneic NK cell therapies, with assets being developed across multiple oncology areas.
Technical Sentiment Signal: Sell
Current Market Cap: A$10.93M
Learn more about CHM stock on TipRanks’ Stock Analysis page.